<ѻýҕl>Oral SERD Tops Fulvestrant for PFS in ER-Positive Breast Cancerѻýҕl> Camizestrant also led to meaningful PFS improvements in those with detectable ESR1 mutations Dec 09, 2022
<ѻýҕl>Continuing CDK4/6 Inhibitor Beyond Progression No Help in Metastatic Breast Cancerѻýҕl> Prior therapy, baseline mutations confound results; "intriguing" benefit with PD-L1 inhibitor Dec 09, 2022
<ѻýҕl>Pausing Endocrine Therapy for Pregnancy Safe in Early Breast Cancerѻýҕl> Study suggests no increased risk of cancer recurrence versus historical control Dec 09, 2022
<ѻýҕl>T-DXd Continues Winning Streak in Metastatic, HER2-Positive Breast Cancerѻýҕl> Trastuzumab deruxtecan improves survival in second- and later-line settings Dec 08, 2022
<ѻýҕl>Neoadjuvant T-DXd Active in HER2-Low Breast Cancerѻýҕl> Response rates on the order of 58-68%, with or without endocrine therapy Dec 08, 2022
<ѻýҕl>Everolimus Fails Again as Adjuvant Therapy for High-Risk Breast Cancerѻýҕl> No improvement in the overall analysis but a hint of benefit in premenopausal patients Dec 08, 2022
<ѻýҕl>Assay Predicts Breast Cancer Patients Who Will Benefit From Ovarian Suppressionѻýҕl> Low score suggests improved outcomes with ovarian suppression plus adjuvant endocrine therapy Dec 07, 2022
<ѻýҕl>First-Line CDK4/6 Thumps Chemo in Aggressive, Advanced Breast Cancerѻýҕl> Doubling of PFS could be death knell for combination chemotherapy in difficult-to-treat subgroup Dec 07, 2022
<ѻýҕl>Metastasis 'Doorway' May Lead to Racial Disparities in Breast Cancerѻýҕl> Density of cellular complex after neoadjuvant therapy tied to cancer subtypes, may be targetable Dec 07, 2022
<ѻýҕl>Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancerѻýҕl> No clear explanation for responses to HER2-targeted drug in HER2-negative tumors Dec 12, 2021
<ѻýҕl>Neratinib-Based Combo Shows Efficacy in HR+, HER2-Mutant Metastatic Breast Cancerѻýҕl> Objective response rate of 42% in patients previously treated with CDK4/6 inhibitors Dec 12, 2021
<ѻýҕl>'Watch and Switch' Strategy Extends PFS in HR-Positive Breast Cancerѻýҕl> Progression-free survival doubled with treatment change based on monitoring for resistance marker Dec 10, 2021
<ѻýҕl>CDK7 Inhibitor-Based Combo Promising in CDK4/6-Resistant Breast Cancerѻýҕl> Clinical benefit rate of 36%, plus tumor shrinkage, with samuraciclib plus fulvestrant Dec 10, 2021
<ѻýҕl>Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancerѻýҕl> Updated PHOEBE trial results now show an overall survival benefit as well Dec 10, 2021
<ѻýҕl>Benefits of Ovarian Suppression Persist in Premenopausal Breast Cancerѻýҕl> Aromatase inhibitor-ovarian suppression tops tamoxifen strategies at 12-13 years Dec 09, 2021
<ѻýҕl>Highly Mutated Breast Cancer Responds to Immunotherapyѻýҕl> Nivolumab-ipilimumab combination associated with durable response in small study Dec 09, 2021
<ѻýҕl>Ribociclib's OS Benefit in Breast Cancer Seen Regardless of Metastatic Siteѻýҕl> Second analysis shows OS benefit consistent across some intrinsic subtypes as well Dec 09, 2021
<ѻýҕl>No Benefit With Metformin in Early Breast Cancer, Regardless of ER/PR Statusѻýҕl> However, there could be improved outcomes in HER2-positive patients Dec 08, 2021
<ѻýҕl>Small PFS Boost With HDAC Inhibitor for Advanced HR-Positive Breast Cancerѻýҕl> Chinese study contradicts U.S. trial that showed no benefit with entinostat add-on Dec 08, 2021
<ѻýҕl>Black Women Most at Risk for Post-Surgical Lymphedemaѻýҕl> Black women seemed to have triple the odds of swelling after axillary lymph node dissection Dec 08, 2021
<ѻýҕl>TROP2-Directed ADC Promising in Advanced Triple-Negative Breast Cancerѻýҕl> Datopotamab deruxtecan turns in solid phase I results Dec 08, 2021
<ѻýҕl>Genomic Profiling Improves Outcomes in Breast Cancerѻýҕl> PFS was better when targeted treatment for genomic alterations was supported by ESCAT criteria Dec 07, 2021
<ѻýҕl>Novel Endocrine Drug Slows Previously Treated HR-Positive Breast Cancerѻýҕl> Elacestrant led to significant improvement in all patients, ESR1-mutant subgroup Dec 07, 2021
<ѻýҕl>Add-On HDAC Inhibitor No Help in Breast Cancerѻýҕl> PFS, OS similar to endocrine therapy alone for advanced HR+ disease Dec 15, 2020
<ѻýҕl>Online Tool Refines Individual Risks in Breast Cancerѻýҕl> RSClin incorporates 21-gene recurrence score with tumor grade, size, and more Dec 13, 2020
<ѻýҕl>Doctor-Patient Discord in Reporting Radiation Toxicityѻýҕl> Physicians underrecognized substantial symptoms in more than half of patients Dec 11, 2020
<ѻýҕl>Adjuvant Palbociclib Fails in Early, High-Risk Breast Cancerѻýҕl> No iDFS benefit with 1 year of CDK4/6 inhibition following neoadjuvant chemotherapy Dec 10, 2020
<ѻýҕl>Oral Paclitaxel Bests IV Delivery in Advanced Breast Cancerѻýҕl> But high pill count, lengthy dosing schedule could prove to be problematic Dec 14, 2019
<ѻýҕl>Residual Breast Cancer Tool Highly Prognostic After Neoadjuvant Txѻýҕl> Tumor burden calculator predicted long-term outcomes in all breast cancer subtypes Dec 14, 2019
<ѻýҕl>Anti-CDK4/6 Fails to Top Chemo in HR-Positive MBCѻýҕl> Similar PFS with chemo, palbociclib plus exemestane or fulvestrant after progression on aromatase inhibitor Dec 13, 2019
<ѻýҕl>HRT Has 20-Year Impact on Breast Cancer Risksѻýҕl> Prospective data confirm long-term benefit with estrogen-only and harm with added progestin Dec 13, 2019
<ѻýҕl>Checkpoints Show Different Outcomes in Breast Cancerѻýҕl> Atezolizumab misses complete response benefit in triple negative patients Dec 13, 2019
<ѻýҕl>T-DM1 Falls Short as Less-Toxic Option for Early Breast Cancerѻýҕl> Promising efficacy but higher discontinuation rates and cost likely a deterrent Dec 13, 2019
<ѻýҕl>Edging Closer to OS Benefit With Novel Anti-HER2 Drugѻýҕl> Larger benefit with margetuximab in most common HER2 breast cancer phenotype Dec 12, 2019
<ѻýҕl>Late-Line HER2 Drug Impresses in Metastatic Breast Cancerѻýҕl> Median PFS over three times better than what is typically seen in this setting, says investigator Dec 11, 2019
<ѻýҕl>New Standard for Metastatic HER2 Breast Cancerѻýҕl> Consistent PFS, OS benefit with combination including oral HER2 inhibitor tucatinib Dec 11, 2019
<ѻýҕl>Patients Say Quality of Life Suffered With Mastectomy for Early Breast Cancerѻýҕl> Breast-conservation options were associated with better sexual, psychosocial outcomes Dec 07, 2018
<ѻýҕl>SABCS: Axillary RT as Good as Surgery in Breast Cancerѻýҕl> Radiation non-inferior to surgery after positive sentinel node Dec 07, 2018
<ѻýҕl>Low-Dose Tamoxifen Feasible Option in Breast Cancerѻýҕl> Women appear to prevent recurrence in early stage cancers with 5 mg dosing Dec 06, 2018
<ѻýҕl>Xeloda Disappoints in Early Triple-Negative Breast Cancerѻýҕl> No improvement after standard chemo, though subset may derive some benefit Dec 05, 2018